| Market Cap | 9.86B 8.63B 7.96B 7.35B 13.95B 941B 14.18B 95.08B 37.34B 463B 37.03B 36.23B 1,593B | P/E 2026 * |
175x | P/E 2027 * | 38.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9.65B 8.44B 7.79B 7.19B 13.64B 920B 13.87B 93.03B 36.53B 453B 36.23B 35.44B 1,559B | EV / Sales 2026 * |
9.59x | EV / Sales 2027 * | 6.71x |
| Free-Float |
65.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 01/01/1999 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 01/03/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 01/01/1999 |
James Wilson
CHM | Chairman | 82 | 01/01/1999 |
David Mahoney
BRD | Director/Board Member | 71 | 01/07/2004 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 9.86B | |
| -2.33% | -2.09% | +49.88% | +170.51% | 1,060B | |
| -0.82% | -2.30% | +63.79% | +62.00% | 619B | |
| -0.73% | -4.98% | +28.91% | +82.99% | 438B | |
| +0.33% | -1.17% | +31.07% | +27.09% | 333B | |
| -0.02% | -2.85% | +29.15% | +45.24% | 282B | |
| -3.89% | -11.22% | +22.81% | +27.30% | 267B | |
| +0.66% | -1.42% | -26.59% | -37.71% | 218B | |
| -0.06% | -2.88% | +23.07% | +62.33% | 196B | |
| -3.72% | -1.10% | +18.41% | +70.56% | 161B | |
| Average | -1.04% | -3.25% | +26.72% | +56.70% | 397.1B | |
| Weighted average by Cap. | -1.31% | -2.96% | +36.75% | +83.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.01B 880M 812M 750M 1.42B 95.95B 1.45B 9.7B 3.81B 47.27B 3.78B 3.7B 163B | 1.4B 1.22B 1.13B 1.04B 1.98B 134B 2.01B 13.5B 5.3B 65.78B 5.26B 5.14B 226B |
| Net income | 85.73M 74.99M 69.17M 63.88M 121M 8.18B 123M 826M 325M 4.03B 322M 315M 13.85B | 369M 322M 297M 275M 521M 35.15B 530M 3.55B 1.4B 17.32B 1.38B 1.35B 59.53B |
| Net Debt | -213M -187M -172M -159M -302M -20.35B -307M -2.06B -808M -10.03B -801M -784M -34.47B | -474M -415M -383M -353M -670M -45.23B -682M -4.57B -1.8B -22.28B -1.78B -1.74B -76.59B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
